Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.28M | 12.69M | 14.18M | 13.95M | 12.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.28M | 12.69M | 14.18M | 13.95M | 12.61M |
| Cost of Revenue | 11.25M | 11.67M | 12.71M | 12.40M | 11.44M |
| Gross Profit | 29.00K | 1.02M | 1.47M | 1.55M | 1.17M |
| SG&A Expenses | 943.00K | 856.00K | 880.00K | 812.00K | 969.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.19M | 12.53M | 13.59M | 13.21M | 12.41M |
| Operating Income | -914.00K | 163.00K | 589.00K | 739.00K | 202.00K |
| Income Before Tax | -874.00K | 196.00K | 595.00K | 778.00K | 185.00K |
| Income Tax Expenses | -112.00K | 73.00K | 773.00K | 167.00K | 69.00K |
| Earnings from Continuing Operations | -762.00K | 123.00K | -178.00K | 611.00K | 116.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -762.00K | 123.00K | -178.00K | 611.00K | 116.00K |
| EBIT | -914.00K | 163.00K | 589.00K | 739.00K | 202.00K |
| EBITDA | -836.00K | 240.00K | 660.00K | 815.00K | 285.00K |
| EPS Basic | -0.02 | 0.00 | -0.01 | 0.02 | 0.00 |
| Normalized Basic EPS | -0.02 | 0.00 | 0.01 | 0.02 | 0.00 |
| EPS Diluted | -0.03 | 0.00 | -0.01 | 0.02 | 0.00 |
| Normalized Diluted EPS | -0.02 | 0.00 | 0.01 | 0.01 | 0.00 |
| Average Basic Shares Outstanding | 31.06M | 31.06M | 30.61M | 30.30M | 30.17M |
| Average Diluted Shares Outstanding | 31.06M | 31.42M | 30.61M | 31.51M | 31.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |